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Background
Malaria is one of the most dangerous tropical diseases
worldwide, resulting in approximately 1.5-2.7 million
deaths per year [1]. Furthermore, malaria belongs to the
four major infectious diseases also including HIV, tuber-
culosis and hepatitis. In humans, malaria is transmitted
by four species of the genus Plasmodium. However,
most malaria deaths are caused by Plasmodium falci-
parum [2].
The Plasmodium falciparum cGMP-dependent protein
kinase (PfPKG) is one of the key regulators of the
malaria parasite life cycle in both sexual and asexual
blood-stages. Inhibition of PfPKG stops differentiation
and transmission of the parasites, indicating that this
kinase is a promising drug target for malaria [3-5].
However, despite its physiological importance, the acti-
vation mechanism of PfPKG is not fully understood.
Recently, our group discovered that disrupting cGMP
binding at the C-terminal cyclic nucleotide-binding
(CNB-D) domain almost completely abolishes the kinase
activation [6]. Therefore, we investigate the functional
role of the PfCNB-D in PfPKG activation.
Results
To investigate the role of the CNB-D in PfPKG activa-
tion, we generated a deletion mutant without the
N-terminal 400 amino acid residues (Δ400), which is
missing a potential auto-inhibitory sequence. We
expressed the deletion construct (PfPKG 401-853) con-
taining the catalytic domain and the PfCNB-D in E. coli.
For the cGMP binding studies we used fluorescence
polarization (FP) assay and for the activation studies we
used microfluidic mobility-shift assay (MSA).
The deletion construct showed similar affinity for
cGMP (40 nM) like the isolated PfCNB-D. In activation,
the Δ400 mutant showed an approximately 3 fold
increased activation constant for cGMP (KA about
240 nM) in comparison to the full length PfPKG (KA
about 70 nM [6]). Unexpectedly, the deletion mutant
exhibited a very low basal activity (about 0.3 U/mg) in
the absence of cGMP. However, it could be activated
efficiently by cGMP (7.0 U/mg), suggesting that the
allosteric activation mechanism of PfPKG is dependent
only on cGMP binding.
In addition, disrupting cGMP binding through mutat-
ing the conserved arginine 492 to lysine (R492K) abol-
ished the cGMP-dependent activation of the deletion
mutant (500-600 fold higher KA for cGMP), suggesting
that the cGMP binding at the CNB-D mainly triggers
the activation of this mutant.
Conclusion
Our results revealed that the activation mechanism of
PfPKG differ from mammalian PKGs. Without the auto-
inhibitory sequence, we expected that the mutant would
completely lose its control on the activity, since the cat-
alytic cleft of the kinase is open. However, without
cGMP the deletion construct (PfPKG 401-853) has a
low basal activity and can be activated efficiently by
cGMP. This suggests that controlling PfPKG activity
may not depend on the interaction between the inhibi-
tory sequence and the catalytic domain. Upon cGMP
binding, conformational changes in the regulatory (R)
domain, especially in the area that bridges the regulatory
and catalytic domains, induce kinase activation.* Correspondence: franz_eugen@yahoo.de
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